Givinostat (ITF-2357) hydrochloride monohydrate is a potent, orally active, pan-HDAC inhibitor with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.
Givinostat (ITF-2357) has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Givinostat (ITF-2357) reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo.
Givinostat (ITF-2357) reduces cytokines and protects islet β cells in vivo and in vitro.
